Abstract
Introduction Scrub typhus is an acute febrile illness caused by the bacterium Orientia tsutsugamushi. Characterizing the population-level burden of scrub typhus is challenging due to the lack of accessible and accurate diagnostics. In this study, we present a novel approach that utilizes information on antibody dynamics after infection to generate population-level scrub typhus seroincidence estimates from cross-sectional serosurveys.
Methods We use data from three cohorts of scrub typhus patients enrolled in Chiang Rai, Thailand, and Vellore, India, and representative population data from two serosurveys in and around the Kathmandu valley, Nepal, and Vellore, India. The samples were tested for IgM and IgG responses to Orientia tsutsugamushi-derived recombinant 56-kDa antigen using commercial ELISA kits. We used Bayesian hierarchical models to fit two-phase models to the antibody responses from scrub typhus cases and used the joint distributions of the peak antibody titers and decay rates to estimate population-level incidence rates in the cross-sectional serosurveys. We compared this new method to a traditional cut-off-based approach for estimating seroincidence.
Results Median IgG antibodies persisted above OD 1.7 for 22 months, while IgM displayed longer persistence than expected, with 50% of participants having an OD >1 for 5 months. We estimated an overall seroincidence of 18 per 1000 person-years (95% CI: 16-21) in India and 4 per 1000 person-years (95% CI: 3-6) in Nepal. Among 18 to 29-year-olds, the seroincidence was 8 per 1000 person-years (95% CI 4 -16) in India and 9 per 1000 person-years (95% CI: 6-14) in Nepal. In both India and Nepal, seroincidence was higher in urban and periurban settings compared to rural areas. Compared to our method, seroincidence estimates derived from age-dependent IgG-seroprevalence without accounting for antibody decay underestimated the disease burden by 50%. By incorporating antibody dynamics, the approach described here provides more accurate age-specific infection risk estimates, emphasizing the importance of considering both IgG and IgM decay patterns in scrub typhus seroepidemiology.
Conclusion The sero-surveillance approach developed in this study efficiently generates population-level scrub typhus seroincidence estimates from cross-sectional serosurveys. This methodology offers a valuable new tool for informing targeted prevention and control strategies, ultimately contributing to a more effective response to scrub typhus in endemic regions worldwide.
- Orientia tsutsugamushi
- Scrub Typhus
- Antibody kinetics
- Seroepidemiology
- incidence
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Fogarty International Center at National Institutes of Health [K01 TW012177-01A1]
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Boards in India (Christian Medical College, Vellore), Thailand (Chiang Rai Hospital, the Faculty of Tropical Medicine, Mahidol University, and the Thai Ministry of Public Health), The United States (Stanford University Institutional Review Board), and Nepal (Nepal Health Research Council Ethical Review Board)) approved the study forms and protocols.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
added additional longitidnal case data. revised the discussion.
Data Availability
Before publication we will make all de-identified data available via Open Science Framework.